Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.39)
# 290
Out of 5,182 analysts
242
Total ratings
44.1%
Success rate
26.27%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Downgrades: Neutral | $123 → $53 | $52.72 | +0.53% | 7 | Apr 6, 2026 | |
| ADMA ADMA Biologics | Downgrades: Neutral | n/a | $11.26 | - | 10 | Mar 26, 2026 | |
| RNAC Cartesian Therapeutics | Upgrades: Overweight | $16 | $6.75 | +137.04% | 1 | Mar 9, 2026 | |
| QURE uniQure | Upgrades: Neutral | $55 → $9 | $18.03 | -50.08% | 11 | Mar 2, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $153 → $125 | $68.85 | +81.55% | 10 | Feb 17, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $7.16 | +165.36% | 2 | Jan 15, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.49 | +0.07% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $19.79 | +142.55% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $7.84 | +206.12% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $5.85 | +224.79% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $24 | $10.08 | +138.10% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $38 | $30.29 | +25.45% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $63 | $49.76 | +26.61% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $24.10 | +335.68% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $68.23 | +72.94% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $53.20 | +39.10% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $7.92 | +102.02% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $35.27 | -14.94% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $20.30 | +299.01% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $6.40 | +9.38% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $4.11 | +2,089.78% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.29 | +2,313.79% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $33.29 | +101.26% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.08 | +316.67% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.91 | +318.85% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.62 | +319.85% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.39 | +233.95% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $0.97 | +1,343.30% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $0.70 | +1,757.14% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.28 | +1,540.63% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.55 | +287.10% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.32 | +6,247.19% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $8.09 | +184.30% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.75 | +119,263.40% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $1.68 | +4,959.52% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.94 | +2,167.00% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.61 | +11,080.12% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.66 | +562.65% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.40 | +4,185.71% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.79 | +11,321.32% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.63 | +401,877.99% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $1.11 | +273,773.87% | 1 | Jan 9, 2020 |
Soleno Therapeutics
Apr 6, 2026
Downgrades: Neutral
Price Target: $123 → $53
Current: $52.72
Upside: +0.53%
ADMA Biologics
Mar 26, 2026
Downgrades: Neutral
Price Target: n/a
Current: $11.26
Upside: -
Cartesian Therapeutics
Mar 9, 2026
Upgrades: Overweight
Price Target: $16
Current: $6.75
Upside: +137.04%
uniQure
Mar 2, 2026
Upgrades: Neutral
Price Target: $55 → $9
Current: $18.03
Upside: -50.08%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $153 → $125
Current: $68.85
Upside: +81.55%
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $7.16
Upside: +165.36%
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.49
Upside: +0.07%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $19.79
Upside: +142.55%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $7.84
Upside: +206.12%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $5.85
Upside: +224.79%
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $10.08
Upside: +138.10%
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $30.29
Upside: +25.45%
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $49.76
Upside: +26.61%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $24.10
Upside: +335.68%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $68.23
Upside: +72.94%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $53.20
Upside: +39.10%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $7.92
Upside: +102.02%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $35.27
Upside: -14.94%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $20.30
Upside: +299.01%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $6.40
Upside: +9.38%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $4.11
Upside: +2,089.78%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.29
Upside: +2,313.79%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $33.29
Upside: +101.26%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.08
Upside: +316.67%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $1.91
Upside: +318.85%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.62
Upside: +319.85%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.39
Upside: +233.95%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $0.97
Upside: +1,343.30%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $0.70
Upside: +1,757.14%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.28
Upside: +1,540.63%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.55
Upside: +287.10%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.32
Upside: +6,247.19%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $8.09
Upside: +184.30%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.75
Upside: +119,263.40%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.68
Upside: +4,959.52%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $7.94
Upside: +2,167.00%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.61
Upside: +11,080.12%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.66
Upside: +562.65%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.40
Upside: +4,185.71%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.79
Upside: +11,321.32%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.63
Upside: +401,877.99%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $1.11
Upside: +273,773.87%